MeiraGTx HoldingsMGTX
MGTX
About: MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Employees: 389
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
20% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 30
10% more capital invested
Capital invested by funds: $171M [Q2] → $189M (+$17.9M) [Q3]
5% more funds holding
Funds holding: 94 [Q2] → 99 (+5) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
4.64% less ownership
Funds ownership: 63.07% [Q2] → 58.43% (-4.64%) [Q3]
67% less call options, than puts
Call options by funds: $87K | Put options by funds: $264K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
79%
upside
Avg. target
$24
282%
upside
High target
$36
485%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin 25% 1-year accuracy 8 / 32 met price target | 485%upside $36 | Buy Maintained | 18 Nov 2024 |
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target | 79%upside $11 | Outperform Maintained | 14 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
MeiraGTx Holdings: Behind The Recent Rally
MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeline includes gene therapies for salivary gland conditions, neurological disorders, and inherited retinal diseases, with multiple BLAs expected from 2024-2027. Recent strategic deals with J&J and Sanofi have bolstered MeiraGTx's financial position, providing a runway into 2Q26 and highlighting strong investor confidence.
Negative
Zacks Investment Research
1 month ago
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.74 per share a year ago.
Positive
Zacks Investment Research
2 months ago
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
Positive
Zacks Investment Research
2 months ago
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Seeking Alpha
2 months ago
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase 3 study designs with regulatory agencies in Q4 2024, potentially initiating late-stage studies in 2025. MeiraGTx secured $50 million in funding, including a $30 million equity investment from Sanofi, enhancing its financial stability for future developments.
Neutral
GlobeNewsWire
2 months ago
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
Negative
Zacks Investment Research
4 months ago
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment
Neutral
GlobeNewsWire
4 months ago
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be $50 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.
Positive
24/7 Wall Street
4 months ago
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
Charts implemented using Lightweight Charts™